VBI Vaccines Inc. (NASDAQ:VBIV) is now being followed by Canaccord Genuity, as they initiated the stock at Buy on November 01. Analysts at Laidlaw, started covering the stock on October 10 with a Buy rating. Analysts at Ladenburg Thalmann, made their first call about the stock on July 26, recommending it is Buy. Noble Financial, released new analyst coverage on May 07, calling the stock is Buy.
VBI Vaccines Inc. (VBIV) hit an intraday high Thursday at $1.81. The shares finished at $1.68, after trading as low as $1.45 earlier in the session. It rose 6.33% in recent trade and currently has a stock-market value of $108.16M. Trading activity significantly improved as the volume at ready counter increased to 3,250,807 shares versus 349,170 in average daily trading volume over the past 20 days. So far this year, the volume has averaged about 234,325 shares. The stock is now 8.39% above against its bear-market low of $1.55 on December 06, 2018. It has retreated -179.76% since it’s 52-week high of $4.7 reached in December. Now the market price is down -60.19% on the year and down -60.66% YTD.
VBIV’s 50 day simple moving average (SMA 50) price is $1.97 and its 200-day simple moving average (SMA 200) price is $2.69. The company’s stock currently has a total float of 39.52M shares. Its weekly volatility is hovering around 9.41% and felt 10.7% volatility in price over a month. On the upside, the share price will test short term resistance at around $1.84. On a downside, the stock is likely to find some support, which begins at $1.48. The failure to get near-term support could push it to $1.29.
Separately, it has been reported that multiple insider activity took place at VBI Vaccines Inc. (VBIV). CEO, President Baxter Jeff acquired 8,100 shares for $233,005 in transaction occurred on 2018/08/06. After making this transaction, the CEO, President owns a direct stake of 15,633 shares, worth $391,448, as per the last closing price. On 2018/08/03 Diaz-Mitoma Francisco, Chief Medical Officer at VBIV, purchased 9,000 shares at an average price of $2.13 per share. The new stake is valued at $513,648.
CEO, President, Baxter Jeff had invested in 13,500 shares for $224,905 through a trade on 2018/08/03. Following this activity, the insider holds 27,135 shares worth $377,840 as of recent close. Wall Street’s most bullish VBI Vaccines Inc. (NASDAQ:VBIV) analysts are predicting the share price to blow past $15.77 per share during the next 12 months. The current median share price forecast by them is $13.19, suggesting that the stock could increase 685.12% in that time frame. The average price target of $14.04 calls for a nearly 735.71% increase in the stock price.
Also, it is trading at rather expensive levels at just over 1.4x price/book and 124.04x price/sales.
Shares of VBI Vaccines Inc. (VBIV) have dropped -27.2% since the company’s last earnings report. Over the past 5 fiscal quarters, VBI Vaccines Inc. (NASDAQ:VBIV) has topped consensus earnings estimates in 1 quarters (14%), missed earnings in 3 quarters (42%), whereas at 1 occasion EPS met analyst expectations. Revenue for the recent quarter stood at $340000, up 36% on last year and below the $1.04 million predicted by analysts. For this quarter, Wall Street analysts forecast revenue in a range of $260000 to $2.03 million, which should be compared with $0 generated last year. EPS is seen in a range of -$1.24E+00 to -$1.19, against the -$0.87 reported a year ago.